Work

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

Year: 2016

Type: article

Abstract: To the editor: Despite the introduction of proteasome inhibitors and immunomodulatory drugs followed by autologous stem cell transplant, most patients with multiple myeloma (MM) will have disease recurrence after primary therapy. Thus, agents with different mechanisms of action and different

Source: Blood

DOI: 10.1182/blood-2016-01-694786

Authors: Nikoletta Lendvai, Andrew J. Yee, Ioanna Tsakos, Aeri Alexander, Sean M. Devlin, Hani Hassoun, Neha Korde, Alexander M. Lesokhin, Heather Landau, Sham Mailankody, Guenther Koehne, David J. Chung, Ola Landgren, Noopur S. Raje, Sergio Giralt

Institutions: Memorial Sloan Kettering Cancer Center, Cornell University, Weill Cornell Medicine, Harvard University, Massachusetts General Hospital

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: Cancer Center Support Grant

OpenAlex ID: W2320360870

FWCI: 2.535

Cites: 11

Cited by: 16

Related to: 10